Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elbasvir/Grazoprevir in Pediatric Chronic HCV
NCT03379506Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of elbasvir, grazoprevir in hepatitis C (HCV), sponsored by Merck & Co.. Started Jan 2018; status: completed.
02
Drugs
elbasvirgrazoprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03379506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03379506.